Literature DB >> 27992627

Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.

Brendan P Lucey1, Kwasi G Mawuenyega2, Bruce W Patterson3, Donald L Elbert4, Vitaliy Ovod2, Tom Kasten2, John C Morris5, Randall J Bateman5.   

Abstract

Importance: Recent studies found that the concentration of amyloid-β (Aβ) fluctuates with the sleep-wake cycle. Although the amplitude of this day/night pattern attenuates with age and amyloid deposition, to our knowledge, the association of Aβ kinetics (ie, production, turnover, and clearance) with this oscillation has not been studied. Objective: To determine the association between Aβ kinetics, age, amyloid levels, and the Aβ day/night pattern in humans. Design, Setting, and Participants: We measured Aβ concentrations and kinetics in 77 adults aged 60 to 87 years with and without amyloid deposition by a novel precise mass spectrometry method at the Washington University School of Medicine in St Louis, Missouri. We compared findings of 2 orthogonal methods, enzyme-linked immunosorbent assay and mass spectrometry, to validate the day/night patterns and determine more precise estimates of the cosinor parameters. In vivo labeling of central nervous system proteins with stable isotopically labeled leucine was performed, and kinetics of Aβ40 and Aβ42 were measured. Interventions: Serial cerebrospinal fluid collection via indwelling lumbar catheter over 36 to 48 hours before, during, and after in vivo labeling, with a 9-hour primed constant infusion of 13C6-leucine. Main Outcomes and Measures: The amplitude, linear increase, and other cosinor measures of each participant's serial cerebrospinal fluid Aβ concentrations and Aβ turnover rates.
Results: Of the 77 participants studied, 46 (59.7%) were men, and the mean (range) age was 72.6 (60.4-87.7) years. Day/night patterns in Aβ concentrations were more sharply defined by the precise mass spectrometry method than by enzyme-linked immunosorbent assay (mean difference of SD of residuals: Aβ40, -7.42 pM; P < .001; Aβ42, -3.72 pM; P < .001). Amyloid deposition diminished day/night amplitude and linear increase of Aβ42 but not of Aβ40. Increased age diminished day/night amplitude of both Aβ40 and Aβ42. After controlling for amyloid deposition, amplitude of Aβ40 was positively associated with production rates (r = 0.42; P < .001), while the linear rise was associated with turnover rates (r = 0.28; P < .05). The amplitude and linear rise of Aβ42 were both associated with turnover (r = -0.38; P < .001) and production (r = 0.238; P < .05) rates. Conclusions and Relevance: Amyloid deposition is associated with premature loss of normal Aβ42 day/night patterns in older adults, suggesting the previously reported effects of age and amyloid on Aβ42 amplitude at least partially affect each other. Production and turnover rates suggest that day/night Aβ patterns are modulated by both production and clearance mechanisms active in sleep-wake cycles and that amyloid deposition may impair normal circadian patterns. These findings may be important for the designs of future secondary prevention trials for Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27992627      PMCID: PMC5305432          DOI: 10.1001/jamaneurol.2016.4202

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  24 in total

1.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

2.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

3.  Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.

Authors:  Diane Slats; Jurgen A H R Claassen; Petra E Spies; George Borm; Kees T C Besse; William van Aalst; Jack Tseng; Magnus J C Sjögren; Marcel G M Olde Rikkert; Marcel M Verbeek
Journal:  Neurobiol Aging       Date:  2011-08-31       Impact factor: 4.673

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels.

Authors:  Jinhe Li; Daniel A Llano; Teresa Ellis; David LeBlond; Anahita Bhathena; Stanford S Jhee; Larry Ereshefsky; Robert Lenz; Jeffrey F Waring
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

6.  Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.

Authors:  Rachel Potter; Bruce W Patterson; Donald L Elbert; Vitaliy Ovod; Tom Kasten; Wendy Sigurdson; Kwasi Mawuenyega; Tyler Blazey; Alison Goate; Robert Chott; Kevin E Yarasheski; David M Holtzman; John C Morris; Tammie L S Benzinger; Randall J Bateman
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

Review 7.  Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis.

Authors:  Brendan P Lucey; Randall J Bateman
Journal:  Neurobiol Aging       Date:  2014-05-15       Impact factor: 4.673

8.  Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial.

Authors:  Sharon Ooms; Sebastiaan Overeem; Kees Besse; Marcel Olde Rikkert; Marcel Verbeek; Jurgen A H R Claassen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

9.  An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

Authors:  Brendan P Lucey; Celedon Gonzales; Ujjwas Das; Jinhe Li; Eric R Siemers; J Randall Slemmon; Randall J Bateman; Yafei Huang; Gerard B Fox; Jurgen A H R Claassen; Diane Slats; Marcel M Verbeek; Gary Tong; Holly Soares; Mary J Savage; Matthew Kennedy; Mark Forman; Magnus Sjögren; Richard Margolin; Xia Chen; Martin R Farlow; Robert A Dean; Jeffrey F Waring
Journal:  Alzheimers Res Ther       Date:  2015-07-29       Impact factor: 6.982

10.  Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors.

Authors:  Bianca Van Broeck; Maarten Timmers; Steven Ramael; Jennifer Bogert; Leslie M Shaw; Marc Mercken; John Slemmon; Luc Van Nueten; Sebastiaan Engelborghs; Johannes Rolf Streffer
Journal:  Alzheimers Res Ther       Date:  2016-05-19       Impact factor: 6.982

View more
  23 in total

1.  Copper-Induced Upregulation of MicroRNAs Directs the Suppression of Endothelial LRP1 in Alzheimer's Disease Model.

Authors:  Heng-Wei Hsu; Carlos J Rodriguez-Ortiz; Siok Lam Lim; Joannee Zumkehr; Jason G Kilian; Janielle Vidal; Masashi Kitazawa
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

2.  Sleep moderates the relationship between amyloid beta and memory recall.

Authors:  Kristine A Wilckens; Dana L Tudorascu; Beth E Snitz; Julie C Price; Howard J Aizenstein; Oscar L Lopez; Kirk I Erickson; Brian J Lopresti; Charles M Laymon; Davneet Minhas; Chester A Mathis; Daniel J Buysse; William E Klunk; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-07-26       Impact factor: 4.673

Review 3.  The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep.

Authors:  Erin L Boespflug; Jeffrey J Iliff
Journal:  Biol Psychiatry       Date:  2017-12-07       Impact factor: 13.382

4.  Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer's Disease.

Authors:  Hari Shanker Sharma; Dafin Fior Muresanu; José Vicente Lafuente; Ranjana Patnaik; Z Ryan Tian; Asya Ozkizilcik; Rudy J Castellani; Herbert Mössler; Aruna Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

5.  Increased Cerebrospinal Fluid Amyloid-β During Sleep Deprivation in Healthy Middle-Aged Adults Is Not Due to Stress or Circadian Disruption.

Authors:  Margaret S Blattner; Sunil K Panigrahi; Cristina D Toedebusch; Terry J Hicks; Jennifer S McLeland; Ian R Banks; Claire Schaibley; Vitaliy Ovod; Kwasi G Mawuenyega; Randall J Bateman; Sharon L Wardlaw; Brendan P Lucey
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics.

Authors:  Brendan P Lucey; Terry J Hicks; Jennifer S McLeland; Cristina D Toedebusch; Jill Boyd; Donald L Elbert; Bruce W Patterson; Jack Baty; John C Morris; Vitaliy Ovod; Kwasi G Mawuenyega; Randall J Bateman
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

7.  Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia.

Authors:  Diego Z Carvalho; Erik K St Louis; David S Knopman; Bradley F Boeve; Val J Lowe; Rosebud O Roberts; Michelle M Mielke; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri
Journal:  JAMA Neurol       Date:  2018-06-01       Impact factor: 18.302

Review 8.  Consequences of Metabolic Disruption in Alzheimer's Disease Pathology.

Authors:  J C Ryu; E R Zimmer; P Rosa-Neto; S O Yoon
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 9.  It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Authors:  Brendan P Lucey
Journal:  Neurobiol Dis       Date:  2020-07-29       Impact factor: 5.996

Review 10.  Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis.

Authors:  Christopher M Henstridge; Bradley T Hyman; Tara L Spires-Jones
Journal:  Nat Rev Neurosci       Date:  2019-02       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.